F H Schroder

Summary

Country: The Netherlands

Publications

  1. ncbi request reprint Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    Prostate 42:107-15. 2000
  2. ncbi request reprint The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Eur Urol 35:539-43. 1999
  3. ncbi request reprint Antiandrogens as monotherapy for prostate cancer
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Eur Urol 34:12-7. 1998
  4. ncbi request reprint Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
    F H Schroder
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    J Natl Cancer Inst 90:1817-23. 1998
  5. pmc Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model
    J Jongsma
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Am J Pathol 154:543-51. 1999
  6. ncbi request reprint Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM)
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, Netherlands Institute for Health Sciences, Rotterdam, The Netherlands
    Urology 63:309-13; discussion 313-5. 2004
  7. ncbi request reprint The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy
    M A Noordzij
    Departments of Urology and Pathology, Erasmus University, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 3:805-15. 1997
  8. ncbi request reprint Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)
    R Kranse
    Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
    Prostate 39:316-22. 1999
  9. ncbi request reprint Different PSA assays lead to detection of prostate cancers with identical histological features
    G Yurdakul
    Department of Urology, University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur Urol 42:154-8. 2002
  10. ncbi request reprint Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    Urology 57:83-90. 2001

Collaborators

Detail Information

Publications51

  1. ncbi request reprint Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    Prostate 42:107-15. 2000
    ..This paper presents a rationale for the use of prostate-specific antigen (PSA) in clinical trials of progressive prostate cancer under endocrine treatment...
  2. ncbi request reprint The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Eur Urol 35:539-43. 1999
    ..Preliminary results with respect to the first round of screening in the Rotterdam area relating to 32,000 randomized men are presented. Evidence of effectiveness of screening through other studies and mechanisms is discussed...
  3. ncbi request reprint Antiandrogens as monotherapy for prostate cancer
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Eur Urol 34:12-7. 1998
    ..No difference was seen in the preservation of sexual functioning. Quality of life issues are becoming increasingly important and thus antiandrogen monotherapy may become more widely used in the management of prostate cancer...
  4. ncbi request reprint Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
    F H Schroder
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    J Natl Cancer Inst 90:1817-23. 1998
    ..Therefore, we evaluated the usefulness of DRE as a stand-alone screening test and in conjunction with measured serum prostate-specific antigen (PSA) levels of 0-3.9 ng/mL and transrectal ultrasonography (TRUS)...
  5. pmc Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model
    J Jongsma
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Am J Pathol 154:543-51. 1999
    ..The strictly androgen-independent NE cells that were still present after 21 days differentiated mainly from G0-phase-arrested cells...
  6. ncbi request reprint Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM)
    M J Roobol
    Department of Urology, Erasmus Medical Centre Rotterdam, Netherlands Institute for Health Sciences, Rotterdam, The Netherlands
    Urology 63:309-13; discussion 313-5. 2004
    ..0 ng/mL or less. Digital rectal examination and/or transrectal ultrasonography have been used as screening tools at these low PSA levels, but this approach is not very efficient...
  7. ncbi request reprint The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy
    M A Noordzij
    Departments of Urology and Pathology, Erasmus University, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 3:805-15. 1997
    ..Loss of CD44s expression in prostate adenocarcinoma predicts a poor prognosis, independent of stage and grade...
  8. ncbi request reprint Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region)
    R Kranse
    Department of Urology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands
    Prostate 39:316-22. 1999
    ..All men with a PSA > or =4 ng/ml and/or a suspicious DRE and/or a suspicious TRUS are biopsied...
  9. ncbi request reprint Different PSA assays lead to detection of prostate cancers with identical histological features
    G Yurdakul
    Department of Urology, University Hospital Rotterdam, Rotterdam, The Netherlands
    Eur Urol 42:154-8. 2002
    ..We analysed five different PSA assays in a biopsy simulation with PSA cut-offs of 3.0 and 4.0 ng/ml...
  10. ncbi request reprint Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital Rotterdam, Rotterdam, The Netherlands
    Urology 57:83-90. 2001
    ..0 ng/mL or greater as the only indication for prostate biopsy with omission of the digital rectal examination (DRE)...
  11. ncbi request reprint Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml)
    A N Vis
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
    Prostate 47:252-61. 2001
    ..The value of rectal examination as initial screening test for prostate cancer at low PSA values (0.0-3.9 ng/ml) was determined by evaluating the number and tumor characteristics of the cancers detected...
  12. ncbi request reprint Lectin-cytochemistry of experimental rat nephrolithiasis
    W C de Bruijn
    AEM Unit, Clinical Pathology Institute, Erasmus University, Rotterdam, The Netherlands
    Scanning Microsc 10:557-76. 1996
    ..WGA/Au-10 nm reaction products mark a crystal matrix component inside intratubular and retained crystals. A similar matrix was also marked by an alpha-osteopontin (alpha OPN/Au-10 nm) reaction product...
  13. ncbi request reprint Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma
    F H Schroder
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Prog Clin Biol Res 359:93-103; discussion 105-7. 1990
    ....
  14. ncbi request reprint Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours
    J C Alers
    Department of Pathology, Eramus University, Rotterdam, The Netherlands
    J Pathol 185:273-83. 1998
    ..03). These data suggest that cancers which recur in time display an intermediate position between tumours of disease-free patients and metastatic cancers...
  15. ncbi request reprint Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience
    Th H van der Kwast
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands and PATHAN Foundation, Rotterdam, The Netherlands
    Can J Urol 12:16-20. 2005
    ..Prostate-specific antigen (PSA) testing of asymptomatic men may lead to the detection of "minimal" prostate cancers that are less likely to be associated with morbidity or mortality...
  16. ncbi request reprint The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy
    R F Hoedemaeker
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands
    BJU Int 92:92-6. 2003
    ....
  17. ncbi request reprint The story of the European Randomized Study of Screening for Prostate Cancer
    F H Schroder
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    BJU Int 92:1-13. 2003
  18. ncbi request reprint Defining the window of opportunity in screening for prostate cancer: validation of a predictive tumor classification model
    A N Vis
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Prostate 46:154-62. 2001
    ..We investigated whether categorization of prostate cancers into different prognostic subgroups is feasible...
  19. pmc Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features
    J C Alers
    Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
    Am J Pathol 158:399-406. 2001
    ..Finally, early localized tumors, as detected by screening programs, harbor cancers with aggressive genetic characteristics...
  20. ncbi request reprint Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines
    J Jongsma
    Department of Experimental Urology, Erasmus University, Rotterdam, The Netherlands
    Prostate 42:34-44. 2000
    ..This may be caused by altered specificity of the androgen receptor (AR), by ligand-independent stimulation of the AR, or by paracrine growth modulation by neuropeptides secreted by neuroendocrine (NE) cells...
  21. ncbi request reprint Human prostate-specific transglutaminase: a new prostatic marker with a unique distribution pattern
    H J Dubbink
    Department of Urology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
    Lab Invest 79:141-50. 1999
    ..The expression pattern as observed for hTGp has not been found thus far for any other prostate-specific marker...
  22. ncbi request reprint Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer
    J B Madalinska
    Department of Public Health, Erasmus University, Rotterdam, The Netherlands
    J Clin Oncol 19:1619-28. 2001
    ....
  23. ncbi request reprint Attachment sites for particles in the urinary tract
    C F Verkoelen
    Department of Urology, Erasmus University and Academic Hospital Dijkzigt, Rotterdam, The Netherlands
    J Am Soc Nephrol 10:S430-5. 1999
    ....
  24. ncbi request reprint Prostate cancer: natural history and surgical treatment of localised disease
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Eur J Cancer 37:S127-36. 2001
    ..Encouragement comes from the increasing volume of evidence showing that poorly differentiated disease can be eradicated as long as it is locally confined...
  25. ncbi request reprint No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam)
    M J Roobol
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Urology 63:892-7; discussion 897-9. 2004
    ..The ERSPC offers the opportunity to study the yield of repeat biopsies after 4 years in men who had negative sextant biopsies and a prostate-specific antigen (PSA) level of 4.0 mg/mL or more at the first screening round...
  26. ncbi request reprint Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project
    M P M Q van Gils
    Department of Urology, Erasmus MC, CA Rotterdam, The Netherlands
    Eur Urol 48:1031-41. 2005
    ..In addition, novel markers will be identified in the same biorepositories by different mass spectrometry techniques...
  27. pmc Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors
    E M Wever
    Department of Public Health, Erasmus Medical Center, P O Box 2040, Rotterdam, 3000, CA, The Netherlands
    Br J Cancer 108:1971-7. 2013
    ..We quantified how the benefits and harms of immediate treatment vary according to the prognostic factors of clinical T-stage, Gleason score, and patient age...
  28. ncbi request reprint Watchful waiting in prostate cancer: review and policy proposals
    F H Schroder
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    BJU Int 92:851-9. 2003
  29. ncbi request reprint Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer
    Stijn H de Vries
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 65:926-30. 2005
    ....
  30. ncbi request reprint Atrophy in prostate needle biopsy cores and its relationship to prostate cancer incidence in screened men
    R Postma
    Department of Urology, Josephine Nefkens Institute, Erasmus Medical Center, Rotterdam, The Netherlands
    Urology 65:745-9. 2005
    ....
  31. ncbi request reprint The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer
    A N Vis
    Department of Pathology, Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, The Netherlands
    Cancer 92:524-34. 2001
    ..The authors assessed whether diagnostic follow-up of men with an initial diagnosis of isolated, high-grade prostatic intraepithelial neoplasia (HPIN) and a prostate biopsy suspicious for malignancy (PBSM) is needed...
  32. doi request reprint The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer
    C Gosselaar
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Prostate 68:985-93. 2008
    ....
  33. ncbi request reprint Screening for prostate cancer
    R Postma
    Department of Urology, Josephine Nefkens Institute, Erasmus MC, P O Box 1738, 3000 DR, Rotterdam, The Netherlands
    Eur J Cancer 41:825-33. 2005
    ..Therefore, until more evidence is available proving otherwise, prostate cancer screening can only be justified in the context of clinical trials...
  34. ncbi request reprint Antiandrogenic substances in the management of prostatic cancer
    F H Schroder
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Recent Results Cancer Res 118:163-73. 1990
    ..The use of antiandrogens is recommended during the initial 4 weeks of management of prostatic carcinoma patients with LH-RH agonists to prevent disease flare-up and to achieve higher early response rates in selective patients...
  35. ncbi request reprint Cell cultures and nephrolithiasis
    C F Verkoelen
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    World J Urol 15:229-35. 1997
    ..Experimental studies that have been performed with cultured renal cells to elucidate the mechanisms involved in these processes will be summarized...
  36. ncbi request reprint Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization
    L C Cao
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Scanning Microsc 10:401-11; discussion 412-4. 1996
    ....
  37. ncbi request reprint Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins
    J P van Brussel
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Eur J Cancer 35:664-71. 1999
    ..Future functional studies, using chemo-selected MDR models, may further help to determine the mechanism or combination of mechanisms underlying the resistance of prostate cancer to chemotherapy...
  38. ncbi request reprint Decreased expression of CD44 in metastatic prostate cancer
    M A Noordzij
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Int J Cancer 84:478-83. 1999
    ..This reduction may be used to predict the N stage clinically, provided that CD44 scores can be determined reliably on preoperative biopsy specimens...
  39. ncbi request reprint Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation
    J Jongsma
    Department of Experimental Urology, Josephine Nefkens Institute, Erasmus University, Rotterdam, The Netherlands
    Cancer Res 60:741-8. 2000
    ....
  40. pmc Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group
    Monique J Roobol
    Department of Urology, Erasmus University Medical Centre, P O Box 2010, 3000 CA, Rotterdam, The Netherlands
    World J Urol 30:149-55. 2012
    ..To compare the predictive performance and potential clinical usefulness of risk calculators of the European Randomized Study of Screening for Prostate Cancer (ERSPC RC) with and without information on prostate volume...
  41. pmc Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Br J Cancer 82:283-90. 2000
    ..Hepatic toxicity may limit the long-term use of both drugs...
  42. ncbi request reprint Very late local recurrence after surgery for prostate cancer unaccompanied by detectable PSA levels
    S Roemeling
    Department of Urology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
    Prostate Cancer Prostatic Dis 9:192-4. 2006
    ..In such exceptional cases, however, PC recurrence would be either missed or would only be diagnosed after a considerable delay...
  43. doi request reprint Blinded and uniform causes of death verification in cancer screening: a major influence on the outcome of a prostate cancer screening trial?
    S J Otto
    Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
    Eur J Cancer 46:3061-7. 2010
    ....
  44. ncbi request reprint Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram
    E W Steyerberg
    Department of Public Health, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 177:107-12; discussion 112. 2007
    ..Statistical models have been proposed to predict indolent cancer. We validated and updated model predictions for a screening setting...
  45. ncbi request reprint Biomarkers and screening for prostate cancer
    F H Schroder
    Department of Urology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
    Ann Oncol 17:x201-6. 2006
  46. ncbi request reprint The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer
    C H Bangma
    Department of Urology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    BJU Int 93:720-4. 2004
    ....
  47. ncbi request reprint Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)
    M J Roobol
    Erasmus Medical Centre, Department of Urology, Rotterdam, The Netherlands
    BJU Int 92:48-54. 2003
    ....
  48. ncbi request reprint Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy
    Stijn H de Vries
    Department of Urology, Erasmus Medical Center and Comprehensive Cancer Center, Rotterdam, The Netherlands
    J Urol 172:2193-6. 2004
    ..We evaluated prostate cancer (PCa) characteristics at diagnosis and changes in prostatic specific antigen (PSA) with time in males with screening detected PCa that was initially managed with a watchful waiting policy...
  49. ncbi request reprint Words of wisdom. Re: Statin drugs and risk of advanced prostate cancer (PC)
    F H Schroder
    Erasmus Medical Centre, Rotterdam, The Netherlands
    Eur Urol 52:1258-9. 2007
  50. ncbi request reprint Adjuvant endocrine treatment in early prostatic cancer
    F H Schroder
    Department of Urology, Erasmus University and Academic Hospital, Rotterdam, The Netherlands
    Acta Oncol 30:255-8. 1991
    ..It is unknown at present whether very early adjuvant treatment may prevent the progression and the promotion of focal disease to clinical prostate cancer. This possibility should be made a subject of future research...
  51. ncbi request reprint Cell type-specific acquired protection from crystal adherence by renal tubule cells in culture
    C F Verkoelen
    Department of Urology, Erasmus University, Rotterdam, The Netherlands
    Kidney Int 55:1426-33. 1999
    ..We now examined whether this property is cell type specific. The susceptibility of the cells to crystal binding was further studied under different culture conditions...